NBIX - More info. on Neurocrine Biosciences Q4 earnings

Neurocrine Biosciences ([[NBIX]] +1.6%) reports Q4 total revenue of $247.9M, +1.6% Y/Y, misses consensus by $20M.GAAP R&D $66.7M vs. last year's $55.3M.Non-GAAP R&D of $59.4 vs. last year's $47.9M.At December 31, 2020, the Company had cash, cash equivalents and debt securities available-for-sale of $1B.INGREZZA net product sales were $240M, representing an increase of 1% vs. 2019 comparable period.Total debt outstanding decreased by $136M to $381M after repurchase of ~26% of debt outstanding during Q4.Non-GAAP EPS of $0.91 beats consensus by $0.01; GAAP EPS of $3.58, not comparable to consensus $0.61."In 2020, we served more patients with tardive dyskinesia than ever before despite the pandemic weighing on the development of the overall market. We are pleased with the recently updated guidelines from the American Psychiatric Association that now recommend first-line treatment for tardive dyskinesia with a VMAT2 inhibitor, which we hope will benefit even more patients as the vast majority of patients living

For further details see:

More info. on Neurocrine Biosciences Q4 earnings